Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

Fabio Efficace; Francesco Cottone; Kathrin Sommer; Jacobien Kieffer; Neil Aaronson; Peter Fayers; Mogens Grønvold; Giovanni Caocci; Francesco Lo Coco; Gianluca Gaidano; Pasquale Niscola; Michele Baccarani; Gianantonio Rosti; Adriano Venditti; Emanuele Angelucci; Paola Fazi; Marco Vignetti; Johannes Giesinger

doi:10.1016/j.jval.2019.06.004

Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

Fabio Efficace, Francesco Cottone, Kathrin Sommer, Jacobien Kieffer, Neil Aaronson, Peter Fayers, Mogens Grønvold, Giovanni Caocci, Francesco Lo Coco, Gianluca Gaidano, Pasquale Niscola, Michele Baccarani, Gianantonio Rosti, Adriano Venditti, Emanuele Angelucci, Paola Fazi, Marco Vignetti, Johannes Giesinger

Section of Health Services Research

5 Citations (Scopus)

Abstract

OBJECTIVES: We investigated the validity of the recently developed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) summary score in patients with hematologic malignancies. Specifically, we evaluated the adequacy of a single-factor measurement model for the QLQ-C30, and its known-groups validity and responsiveness to change over time.

METHODS: We used confirmatory factor analysis to test the single-factor model of the QLQ-C30, using baseline QLQ-C30 data (N = 2134). The QLQ-C30 summary score was compared to the original QLQ-C30 scales using general (age, sex, Eastern Cooperative Oncology Group performance status, comorbidity) and disease-specific (red blood cell transfusion dependency) groups. Repeated measurements allowed us to investigate responsiveness to change in a subgroup of patients with acute myeloid leukemia.

RESULTS: The single-factor model of the QLQ-C30 exhibited adequate fit in patients with hematologic malignancies. Known-group comparisons generally supported the construct validity of the summary score when using more general grouping variables (sociodemographics, broad clinical parameters). Nevertheless, when groups were formed on the basis of disease-specific variables (eg, transfusion dependency), the summary score performed less well the some of the original, separate scales of the QLQ-C30.

CONCLUSION: Our findings provide support for the validity of the single-factor model of the EORTC QLQ-C30 in patients with hematologic malignancies. Specifically, the results suggest that the summary score can be used as an endpoint in this population when symptom- or other health domain-specific hypotheses are not available.

Original language	English
Journal	Value in Health
Volume	22
Issue number	11
Pages (from-to)	1303-1310
Number of pages	8
ISSN	1098-3015
DOIs	https://doi.org/10.1016/j.jval.2019.06.004
Publication status	Published - Nov 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jval.2019.06.004

http://www.valueinhealthjournal.com/article/S1098301519322521/pdf

Cite this

Efficace, F., Cottone, F., Sommer, K., Kieffer, J., Aaronson, N., Fayers, P., Grønvold, M., Caocci, G., Lo Coco, F., Gaidano, G., Niscola, P., Baccarani, M., Rosti, G., Venditti, A., Angelucci, E., Fazi, P., Vignetti, M., & Giesinger, J. (2019). Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. Value in Health, 22(11), 1303-1310. https://doi.org/10.1016/j.jval.2019.06.004

Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. / Efficace, Fabio; Cottone, Francesco; Sommer, Kathrin et al.
In: Value in Health, Vol. 22, No. 11, 11.2019, p. 1303-1310.

Research output: Contribution to journal › Journal article › Research › peer-review

Efficace, F, Cottone, F, Sommer, K, Kieffer, J, Aaronson, N, Fayers, P, Grønvold, M, Caocci, G, Lo Coco, F, Gaidano, G, Niscola, P, Baccarani, M, Rosti, G, Venditti, A, Angelucci, E, Fazi, P, Vignetti, M & Giesinger, J 2019, 'Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies', Value in Health, vol. 22, no. 11, pp. 1303-1310. https://doi.org/10.1016/j.jval.2019.06.004

@article{0bc08baf9e6a4185a0effe90bef4c859,

title = "Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies",

abstract = "OBJECTIVES: We investigated the validity of the recently developed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) summary score in patients with hematologic malignancies. Specifically, we evaluated the adequacy of a single-factor measurement model for the QLQ-C30, and its known-groups validity and responsiveness to change over time.METHODS: We used confirmatory factor analysis to test the single-factor model of the QLQ-C30, using baseline QLQ-C30 data (N = 2134). The QLQ-C30 summary score was compared to the original QLQ-C30 scales using general (age, sex, Eastern Cooperative Oncology Group performance status, comorbidity) and disease-specific (red blood cell transfusion dependency) groups. Repeated measurements allowed us to investigate responsiveness to change in a subgroup of patients with acute myeloid leukemia.RESULTS: The single-factor model of the QLQ-C30 exhibited adequate fit in patients with hematologic malignancies. Known-group comparisons generally supported the construct validity of the summary score when using more general grouping variables (sociodemographics, broad clinical parameters). Nevertheless, when groups were formed on the basis of disease-specific variables (eg, transfusion dependency), the summary score performed less well the some of the original, separate scales of the QLQ-C30.CONCLUSION: Our findings provide support for the validity of the single-factor model of the EORTC QLQ-C30 in patients with hematologic malignancies. Specifically, the results suggest that the summary score can be used as an endpoint in this population when symptom- or other health domain-specific hypotheses are not available.",

author = "Fabio Efficace and Francesco Cottone and Kathrin Sommer and Jacobien Kieffer and Neil Aaronson and Peter Fayers and Mogens Gr{\o}nvold and Giovanni Caocci and {Lo Coco}, Francesco and Gianluca Gaidano and Pasquale Niscola and Michele Baccarani and Gianantonio Rosti and Adriano Venditti and Emanuele Angelucci and Paola Fazi and Marco Vignetti and Johannes Giesinger",

year = "2019",

month = nov,

doi = "10.1016/j.jval.2019.06.004",

language = "English",

volume = "22",

pages = "1303--1310",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

AU - Efficace, Fabio

AU - Cottone, Francesco

AU - Sommer, Kathrin

AU - Kieffer, Jacobien

AU - Aaronson, Neil

AU - Fayers, Peter

AU - Grønvold, Mogens

AU - Caocci, Giovanni

AU - Lo Coco, Francesco

AU - Gaidano, Gianluca

AU - Niscola, Pasquale

AU - Baccarani, Michele

AU - Rosti, Gianantonio

AU - Venditti, Adriano

AU - Angelucci, Emanuele

AU - Fazi, Paola

AU - Vignetti, Marco

AU - Giesinger, Johannes

PY - 2019/11

Y1 - 2019/11

N2 - OBJECTIVES: We investigated the validity of the recently developed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) summary score in patients with hematologic malignancies. Specifically, we evaluated the adequacy of a single-factor measurement model for the QLQ-C30, and its known-groups validity and responsiveness to change over time.METHODS: We used confirmatory factor analysis to test the single-factor model of the QLQ-C30, using baseline QLQ-C30 data (N = 2134). The QLQ-C30 summary score was compared to the original QLQ-C30 scales using general (age, sex, Eastern Cooperative Oncology Group performance status, comorbidity) and disease-specific (red blood cell transfusion dependency) groups. Repeated measurements allowed us to investigate responsiveness to change in a subgroup of patients with acute myeloid leukemia.RESULTS: The single-factor model of the QLQ-C30 exhibited adequate fit in patients with hematologic malignancies. Known-group comparisons generally supported the construct validity of the summary score when using more general grouping variables (sociodemographics, broad clinical parameters). Nevertheless, when groups were formed on the basis of disease-specific variables (eg, transfusion dependency), the summary score performed less well the some of the original, separate scales of the QLQ-C30.CONCLUSION: Our findings provide support for the validity of the single-factor model of the EORTC QLQ-C30 in patients with hematologic malignancies. Specifically, the results suggest that the summary score can be used as an endpoint in this population when symptom- or other health domain-specific hypotheses are not available.

AB - OBJECTIVES: We investigated the validity of the recently developed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) summary score in patients with hematologic malignancies. Specifically, we evaluated the adequacy of a single-factor measurement model for the QLQ-C30, and its known-groups validity and responsiveness to change over time.METHODS: We used confirmatory factor analysis to test the single-factor model of the QLQ-C30, using baseline QLQ-C30 data (N = 2134). The QLQ-C30 summary score was compared to the original QLQ-C30 scales using general (age, sex, Eastern Cooperative Oncology Group performance status, comorbidity) and disease-specific (red blood cell transfusion dependency) groups. Repeated measurements allowed us to investigate responsiveness to change in a subgroup of patients with acute myeloid leukemia.RESULTS: The single-factor model of the QLQ-C30 exhibited adequate fit in patients with hematologic malignancies. Known-group comparisons generally supported the construct validity of the summary score when using more general grouping variables (sociodemographics, broad clinical parameters). Nevertheless, when groups were formed on the basis of disease-specific variables (eg, transfusion dependency), the summary score performed less well the some of the original, separate scales of the QLQ-C30.CONCLUSION: Our findings provide support for the validity of the single-factor model of the EORTC QLQ-C30 in patients with hematologic malignancies. Specifically, the results suggest that the summary score can be used as an endpoint in this population when symptom- or other health domain-specific hypotheses are not available.

U2 - 10.1016/j.jval.2019.06.004

DO - 10.1016/j.jval.2019.06.004

M3 - Journal article

C2 - 31708068

SN - 1098-3015

VL - 22

SP - 1303

EP - 1310

JO - Value in Health

JF - Value in Health

IS - 11

ER -

Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this